Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (321-330 of 386) with videos related to

Pageof 39
Sort By:
Cancer Biology & Therapy|April 2, 2008
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivoHossein Hamed, Clint Mitchell, Margaret A Park, et al.
Molecular Cancer Therapeutics|February 17, 2005
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survivalRubén W Carón, Adly Yacoub, Min Li, et al.
British Journal of Haematology|October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivoLin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activationGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2010
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant gliomaHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Cancer Research|January 28, 2010
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cellsAdly Yacoub, Hossein A Hamed, Jeremy Allegood, et al.
Medical Oncology (Northwood, London, England)|February 23, 2024
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemiaIan M Bouligny, Graeme Murray, Michael Doyel, et al.
Leukemia Research|September 2, 2023
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemiaIan M Bouligny, Graeme Murray, Thuy Ho, et al.
Research Square|July 3, 2023
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaIan M Bouligny, Graeme Murray, Thuy Ho, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2024
Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant GliomaHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Pageof 39

Showing results (321-330 of 386) with videos related to

Sort By:
Pageof 39
Cancer Biology & Therapy|April 2, 2008
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivoHossein Hamed, Clint Mitchell, Margaret A Park, et al.
Molecular Cancer Therapeutics|February 17, 2005
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survivalRubén W Carón, Adly Yacoub, Min Li, et al.
British Journal of Haematology|October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivoLin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activationGuo Zhang, Margaret A Park, Clint Mitchell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2010
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant gliomaHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Cancer Research|January 28, 2010
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cellsAdly Yacoub, Hossein A Hamed, Jeremy Allegood, et al.
Medical Oncology (Northwood, London, England)|February 23, 2024
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemiaIan M Bouligny, Graeme Murray, Michael Doyel, et al.
Leukemia Research|September 2, 2023
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemiaIan M Bouligny, Graeme Murray, Thuy Ho, et al.
Research Square|July 3, 2023
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaIan M Bouligny, Graeme Murray, Thuy Ho, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2024
Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant GliomaHossein A Hamed, Adly Yacoub, Margaret A Park, et al.
Pageof 39